Ipca Laboratories Resultados de beneficios anteriores

Pasado controles de criterios 2/6

Los beneficios de Ipca Laboratories han disminuido a una tasa media anual de -3.5%, mientras que en la industria Pharmaceuticals los beneficios crecieron en un 14.8% anualmente. Los ingresos han ido creciendo a una tasa media de 10.7% al año. La rentabilidad financiera de Ipca Laboratories es de 7.9%, y sus márgenes netos son de 7.9%.

Información clave

-3.5%

Tasa de crecimiento de los beneficios

-3.6%

Tasa de crecimiento del BPA

Crecimiento de la industria Pharmaceuticals	17.5%
Tasa de crecimiento de los ingresos	10.7%
Rentabilidad financiera	7.9%
Margen neto	7.9%
Última actualización de beneficios	31 Dec 2023

Actualizaciones de resultados anteriores recientes

Recent updates

These 4 Measures Indicate That Ipca Laboratories (NSE:IPCALAB) Is Using Debt Reasonably Well

Sep 20

Is Now The Time To Put Ipca Laboratories (NSE:IPCALAB) On Your Watchlist?

Aug 09

Does Ipca Laboratories (NSE:IPCALAB) Have A Healthy Balance Sheet?

Jun 08

How Does Ipca Laboratories Limited (NSE:IPCALAB) Stand Up To These Simple Dividend Safety Checks?

Mar 26

Do Ipca Laboratories's (NSE:IPCALAB) Earnings Warrant Your Attention?

Mar 13

Trade Alert: The Compliance Officer Of Ipca Laboratories Limited (NSE:IPCALAB), Harish Kamath, Has Sold Some Shares Recently

Feb 28

Ipca Laboratories Limited's (NSE:IPCALAB) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Feb 23

Does Ipca Laboratories' (NSE:IPCALAB) CEO Salary Compare Well With Industry Peers?

Feb 11

Could The Ipca Laboratories Limited (NSE:IPCALAB) Ownership Structure Tell Us Something Useful?

Jan 30

The Ipca Laboratories (NSE:IPCALAB) Share Price Is Up 264% And Shareholders Are Boasting About It

Jan 15

Ipca Laboratories (NSE:IPCALAB) Seems To Use Debt Rather Sparingly

Dec 31

Don't Ignore The Fact That This Insider Just Sold Some Shares In Ipca Laboratories Limited (NSE:IPCALAB)

Dec 16

The Case For Ipca Laboratories Limited (NSE:IPCALAB): Could It Be A Nice Addition To Your Dividend Portfolio?

Dec 13

This Insider Has Just Sold Shares In Ipca Laboratories Limited (NSE:IPCALAB)

Nov 28

Is Now The Time To Put Ipca Laboratories (NSE:IPCALAB) On Your Watchlist?

Nov 25

Ipca Laboratories Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Nov 10

Is Ipca Laboratories Limited's (NSE:IPCALAB) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Nov 08

Do Insiders Own Lots Of Shares In Ipca Laboratories Limited (NSE:IPCALAB)?

Oct 24

Ipca Laboratories' (NSE:IPCALAB) Wonderful 327% Share Price Increase Shows How Capitalism Can Build Wealth

Oct 09

What We Learned About Ipca Laboratories' (NSE:IPCALAB) CEO Compensation

Sep 24

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Ipca Laboratories. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NSEI:IPCALAB Ingresos, gastos y beneficios (INR Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
31 Dec 23	71,875	5,643	15,923	0
30 Sep 23	66,806	4,922	14,517	0
30 Jun 23	62,500	4,911	13,450	0
31 Mar 23	62,481	4,713	13,102	0
31 Dec 22	60,225	5,250	12,779	0
30 Sep 22	59,070	6,142	12,431	0
30 Jun 22	58,505	7,205	12,204	0
31 Mar 22	58,305	8,841	11,972	0
31 Dec 21	56,561	9,152	11,555	0
30 Sep 21	56,355	9,837	11,169	0
30 Jun 21	54,521	10,005	10,751	0
31 Mar 21	54,207	11,400	10,318	0
31 Dec 20	53,802	10,647	10,135	0
30 Sep 20	51,833	9,968	9,997	0
30 Jun 20	51,061	9,228	9,772	0
31 Mar 20	46,499	6,063	9,366	0
31 Dec 19	44,563	6,189	8,911	0
30 Sep 19	42,496	5,804	8,455	0
30 Jun 19	39,777	5,059	8,254	0
31 Mar 19	37,750	4,448	8,123	0
31 Mar 18	32,852	2,394	7,604	0
31 Mar 17	31,562	1,945	7,182	0
31 Mar 16	28,671	931	6,474	0
31 Mar 15	31,444	2,542	5,872	0
31 Mar 14	32,818	4,785	9,200	852

Ingresos de calidad: IPCALAB tiene ganancias de alta calidad.

Margen de beneficios creciente: Los actuales márgenes de beneficio(7.9%) de IPCALAB son inferiores a los del año pasado (8.7%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: Los beneficios de IPCALAB han disminuido en un 3.5% al año en los últimos 5 años.

Acelerando crecimiento: El crecimiento de los beneficios de IPCALAB en el último año (7.5%) supera su media de 5 años (-3.5% al año).

Beneficios vs. Industria: El crecimiento de los beneficios de IPCALAB en el último año (7.5%) no superó al de la industria Pharmaceuticals 23.8%.

Ipca Laboratories Resultados de beneficios anteriores

Pasado controles de criterios 2/6

Información clave

Actualizaciones de resultados anteriores recientes

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Ipca Laboratories Limited to Report Q3, 2024 Results on Feb 14, 2024

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Ipca Laboratories Limited to Report Q2, 2024 Results on Nov 10, 2023

Ipca Laboratories Limited to Report Q1, 2024 Results on Aug 10, 2023

Full year 2023 earnings: EPS misses analyst expectations

Recent updates

Ipca Laboratories Limited Announces Cessation of Anand T. Kusre as an Independent Director

Price target increased by 9.1% to ₹1,097

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Investors Interested In Ipca Laboratories Limited's (NSE:IPCALAB) Earnings

Ipca Laboratories Limited to Report Q3, 2024 Results on Feb 14, 2024

Here's Why Ipca Laboratories (NSE:IPCALAB) Can Manage Its Debt Responsibly

CFO, MD & Executive Director recently sold ₹22m worth of stock

Price target increased by 9.7% to ₹987

Upcoming dividend of ₹2.00 per share at 0.2% yield

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Ipca Laboratories Limited to Report Q2, 2024 Results on Nov 10, 2023

Ipca Laboratories Limited Appoints Hitesh Kumar Maheshwari as President R&D (Formulations)

Is Ipca Laboratories (NSE:IPCALAB) A Risky Investment?

Ipca Laboratories Limited to Report Q1, 2024 Results on Aug 10, 2023

Full year 2023 earnings: EPS misses analyst expectations

Ipca Laboratories Limited, Annual General Meeting, Aug 10, 2023

Full year 2023 earnings: EPS misses analyst expectations

Ipca Laboratories Limited to Report Q4, 2023 Results on May 29, 2023

Price target decreased by 7.1% to ₹858

Investor sentiment deteriorates as stock falls 15%

Ipca Laboratories (NSE:IPCALAB) Has A Pretty Healthy Balance Sheet

Consensus EPS estimates fall by 21%

Third quarter 2023 earnings: EPS misses analyst expectations

Ipca Laboratories Limited to Report Q3, 2023 Results on Feb 14, 2023

Ipca Laboratories Limited (BSE:524494)acquired additional 6.53% stake in Trophic Wellness Pvt. Ltd. for INR 105.8 million.

Insufficient new directors

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Ipca Laboratories Limited Declares Interim Dividend for the Financial Year 2022-23, Payable on December 7, 2022

Ipca Laboratories Limited to Report Q2, 2023 Results on Nov 11, 2022

Ipca Laboratories Limited Announces Board Meeting Outcome for Appointment Of Dr. Narendra Mairpady (DIN 00536905) As A Director / Independent Director

Ipca Laboratories Limited Announces Board Meeting Outcome for Appointment Of Dr. Narendra Mairpady (DIN 00536905) As A Director / Independent Director

Insider recently sold ₹1.7m worth of stock

Here's Why Ipca Laboratories (NSE:IPCALAB) Can Manage Its Debt Responsibly

Estimating The Intrinsic Value Of Ipca Laboratories Limited (NSE:IPCALAB)

Ipca Laboratories Limited Approves Interim Dividend as Final Dividend for Financial Year Ended 31St March, 2022

Now 20% undervalued

Ipca Laboratories Limited Announced Demise of Dev Parkash Yadava, Non-Executive and Independent Director

Ipca Laboratories Limited to Report Q1, 2023 Results on Aug 10, 2022

Now 20% undervalued after recent price drop

Full year 2022 earnings: EPS misses analyst expectations

Ipca Laboratories Limited, Annual General Meeting, Aug 10, 2022

Now 20% undervalued after recent price drop

Is Ipca Laboratories (NSE:IPCALAB) A Risky Investment?

Now 20% undervalued after recent price drop

Price target decreased to ₹1,067

Calculating The Fair Value Of Ipca Laboratories Limited (NSE:IPCALAB)

Full year 2022 earnings: EPS misses analyst expectations

Insufficient new directors

CFO, Joint MD & Executive Director recently sold ₹21m worth of stock

Does Ipca Laboratories (NSE:IPCALAB) Have A Healthy Balance Sheet?

Price target decreased to ₹1,177

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Ipca Laboratories Limited to Report Q3, 2022 Results on Feb 14, 2022

Ipca Laboratories Limited (BSE:524494) made an offer to acquire additional 26% stake in Lyka Labs Limited (BSE:500259) from Mayank J Shah, Shruti M Shah, Prasham M Shah and others for approximately INR 970 million.

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS ₹19.73 (vs ₹21.08 in 2Q 2021)

These 4 Measures Indicate That Ipca Laboratories (NSE:IPCALAB) Is Using Debt Reasonably Well

Price target increased to ₹2,442

Insider recently sold ₹3.8m worth of stock

Is Now The Time To Put Ipca Laboratories (NSE:IPCALAB) On Your Watchlist?

First quarter 2022 earnings released: EPS ₹24.18 (vs ₹28.18 in 1Q 2021)

Ipca Laboratories Limited (BSE:524494) acquired 13.09% stake in Trophic Wellness Pvt. Ltd. INR 210 million.

Does Ipca Laboratories (NSE:IPCALAB) Have A Healthy Balance Sheet?

Full year 2021 earnings released: EPS ₹90.11 (vs ₹47.99 in FY 2020)

Insider recently bought ₹1.9m worth of stock

How Does Ipca Laboratories Limited (NSE:IPCALAB) Stand Up To These Simple Dividend Safety Checks?

Do Ipca Laboratories's (NSE:IPCALAB) Earnings Warrant Your Attention?

Trade Alert: The Compliance Officer Of Ipca Laboratories Limited (NSE:IPCALAB), Harish Kamath, Has Sold Some Shares Recently

Compliance Officer recently sold ₹13m worth of stock

Desglose de ingresos y gastos
Beta